Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

MARITIME-2

Amgen · Phase 3 · Active, not recruiting · Enrollment 1105

NCT06858878

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide High DoseObesity + T2Dn/rn/rn/rn/r
Maridebart Cafraglutide Medium DoseObesity + T2Dn/rn/rn/rn/r
Maridebart Cafraglutide Low DoseObesity + T2Dn/rn/rn/rn/r
PlaceboObesity + T2Dn/rn/rn/rn/r